id: naltrexone_treatment_to_alcohol_consumption_reduction
name: Naltrexone Pharmacotherapy â†’ Reduction in Heavy Alcohol Consumption
from_node:
  node_id: naltrexone_treatment
  node_name: Naltrexone Pharmacotherapy
to_node:
  node_id: alcohol_consumption_reduction
  node_name: Reduction in Heavy Alcohol Consumption
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Naltrexone antagonizes opioid receptors involved in alcohol reward pathways'
- 'Step 2: Blockade of mu-opioid receptors reduces euphoric effects of alcohol consumption'
- 'Step 3: Diminished reward response decreases motivation to engage in heavy drinking
  episodes'
- 'Step 4: Reduced heavy drinking days contribute to improved alcohol use disorder
  outcomes'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Kirsten C Morley et al. 2024. "Topiramate Versus Naltrexone for
    Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled
    Trial.." *American Journal of Psychiatry*. https://doi.org/10.1176/appi.ajp.20230666'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.666395'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: rs1799971_polymorphism
  direction: weakens
  strength: weak
  description: OPRM1 polymorphism rs1799971 showed no effect on naltrexone treatment
    response, contrary to prior literature suggesting pharmacogenetic effects
